Jiangsu Nhwa Pharmaceutical: H1 revenue and net profit rose 15%+ on CNS drug growth and robust R&D pipeline

About this update from Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

Revenue and net profit grew over 15% year-over-year, driven by CNS drug innovation and strong anesthesia product sales. R&D investment rose 13%, with over 70 projects in the pipeline. No interim dividend planned.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A